Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first
- 1 August 2014
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 19 (8) , 1251-1256
Abstract
No abstract availableKeywords
Funding Information
- Fondation pour la Recherche Médicale (DEQ20100318257)
This publication has 70 references indexed in Scilit:
- Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary HypertensionCirculation Research, 2011
- Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertensionRespiratory Research, 2010
- T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertensionRespiratory Medicine, 2010
- Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial HypertensionInternational Journal of Rheumatology, 2010
- Absence of T Cells Confers Increased Pulmonary Arterial Hypertension and Vascular RemodelingAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell functionJournal of Clinical Investigation, 2007
- 1. Systemic Lupus ErythematosusNihon Naika Gakkai Zasshi, 2007
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJournal of Experimental Medicine, 2006
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Endothelium as a target for antiphospholipid antibodiesImmunobiology, 2003